Preformulation study of the vaccine candidate TAB9 against HIV-1.

Autor: Expósito Raya N; Departamento de Desarrollo de Formulaciones, Centro de Ingenieri;a Genética y Biotecnologi;a, P.O. Box 6162, Cubanacán, Havana 10600, Cuba., García Díaz A, Carrazana López Y, Quintana Vazquez D, Pichardo Díaz D, Martínez de la Puente N, Duarte Cano C
Jazyk: angličtina
Zdroj: Biotechnology and applied biochemistry [Biotechnol Appl Biochem] 2002 Oct; Vol. 36 (2), pp. 149-53.
DOI: 10.1042/ba20020048
Abstrakt: A preformulation study was performed for the evaluation of a vaccine candidate against HIV-1. Aluminium hydroxide was used in the preformulation. However, this adjuvant is not a good adsorbent for basic proteins since it is positively charged at a physiological pH. In the present study, we determined the adsorption of TAB9 (basic protein, pI: 11.3) by treating Alhydrogel with different ions. The immunogenicity of the vaccine candidate against HIV was also evaluated using three batches, 9801-A, 9802-A and 9803-A, and a placebo P-001. The evaluation was performed twice (0 and 9 months). Each batch was tested using groups of 10 mice that had a single inoculation. The results showed that the protein was totally adsorbed to the aluminium gel. Seroconvertion was attained in all analysed batches, indicating the potentiality of TAB9 as a vaccine candidate.
Databáze: MEDLINE